We are a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation, or MV, which is the standard of care today for the treatment of respiratory failure. Although it may be lifesaving, MV is associated with increased costs of care, extended lengths of stay in the hospital, frequent incidence of infections, ventilator dependence and mortality. The COVID-19 pandemic has further exposed the weaknesses and disadvantages of invasive MV that has both high association with considerable medical risks and iatrogenic complications, which further burdens the healthcare system with long hospital stays and high costs of treatment.

We have developed a direct blood oxygenation technology called Augmented Respiration Technology, or ART. Our device, the ART500, is comprised of a minimally invasive, portable dual lumen cannula which is inserted into the jugular vein and utilizes our extra-corporeal direct blood oxygenation unit to elevate and stabilize declining oxygen saturation levels. The ART500’s structure provides the potential to extend respiratory treatment beyond ICU environments, making acute respiratory treatment available in regions and medical facilities without the need for ICUs.

Our ART500 is designed to treat patients while awake, mobile and breathing spontaneously. Although our ART500 has not been tested in humans, and is not cleared or approved by the U.S. Food and Drug Administration, or FDA, or similar foreign regulatory bodies, we believe that our ART500 has the potential to reduce the patients’ length of stay in the ICU, as well as to reduce the rehabilitation period in the hospital due to the absence of the need to wean the patients after MV intubation that requires medically induced coma, and reduce the incidence of hospital re-admissions compared to MV.

Note: We have not generated any revenues from the sale of our products. Net loss figure is for the year ended Dec. 31, 2020.

(Note: Inspira Technologies OXY B.H.N. upsized its micro-cap IPO at pricing on July 13, 2021, to 2.91 million units – up from 2.31 million units in the prospectus –  at $5.51 each, the low end of its $5.50 to $7.50 price range, to raise $16 million. Each unit consists of one share and a warrant to buy one share. The shares, under the symbol IINN, and the warrants, under the symbol IINNW, are expected to start trading Wednesday, July 14, 2021, on the NASDAQ. This IPO, which was filed initially in early March as a stock offering, was restructured in June as a unit offering. The company also switched underwriters. The deal had been among those expected to get priced during the week of April 5, 2021.)